Pure Financial Advisors LLC Has $775,000 Holdings in Pfizer Inc. (NYSE:PFE)

Pure Financial Advisors LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 3.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,701 shares of the biopharmaceutical company’s stock after selling 894 shares during the period. Pure Financial Advisors LLC’s holdings in Pfizer were worth $775,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Olistico Wealth LLC bought a new position in shares of Pfizer during the second quarter worth approximately $25,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer in the fourth quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new position in Pfizer during the fourth quarter worth about $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

Pfizer stock traded down $0.41 during mid-day trading on Friday, reaching $28.30. The company had a trading volume of 50,332,917 shares, compared to its average volume of 39,558,848. The business has a fifty day simple moving average of $28.75 and a 200 day simple moving average of $27.89. The company has a market cap of $160.36 billion, a P/E ratio of -471.59, a P/E/G ratio of 0.99 and a beta of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.19. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $0.67 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.94%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.